ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2025
0mins
Source: Globenewswire
Microglial Inflammation in Parkinson's Disease: Recent studies highlight the role of microglial-driven inflammation in the accumulation of toxic phosphorylated alpha-synuclein, which contributes to neurodegeneration in Parkinson's Disease. The Inflammasome ASC Inhibitor IC 100 has shown promise in reducing this inflammation and potentially modifying disease progression.
ZyVersa Therapeutics' Developments: ZyVersa Therapeutics is advancing its research on IC 100 as a treatment for Parkinson's Disease, with plans to initiate proof-of-concept studies in animal models. The company aims to address the significant unmet medical need for therapies that slow the progression of Parkinson's, which currently affects over 10 million people worldwide.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
